drugset / Trial / NCT03457818

Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

NCT03457818

Phase 2 Terminated 8 enrolled Mishaela Rubin
RandomizedParallel-groupDouble-blindPrevention

Summary

The goal of the study is to characterize the effect of Prolia® (denosumab) on indices of bone strength in type 2 diabetes (T2D). The investigational plan involves administration of Prolia® or identical placebo for 12 months as a randomized double-blind placebo-controlled trial in 66 T2D postmenopausal women assigned to Prolia® or placebo. The study will include assessment of different measures of bone quality: skeletal microarchitecture, including measurement of skeletal cortical pores; bone mineral density; bone material quality, and accumulation of advanced glycation endproducts (AGEs) in collagen. This information will help to determine whether Prolia® treatment in type 2 diabetes has skeletal benefits.

Timeline

Start
2018-11-07
Primary completion
2020-06-10
Completion
2020-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 60 mg Subcutaneous